ARS Pharmaceuticals, Inc. SPRY Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s financing cash flow?
- ARS Pharmaceuticals, Inc. (SPRY) reported financing cash flow of $159K in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s financing cash flow changed year-over-year?
- ARS Pharmaceuticals, Inc.'s financing cash flow decreased by 78.1% year-over-year, from $725K to $159K.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s financing cash flow?
- Over 4 years (2021 to 2025), ARS Pharmaceuticals, Inc.'s financing cash flow has grown at a 18.4% compound annual growth rate (CAGR), from $53.16M to $104.6M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.